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Board Member Spotlight: 









Dr. Mark Santillan, MD, brings a great 
deal of energy to his position as 
Assistant Professor in the Division of 
Maternal-Fetal Medicine, Department of 
Obstetrics and Gynecology, University 
of Iowa. As an active physician in the 
high-risk obstetrics clinic, researcher 
into the causes of preeclampsia, and 
Clinical Research Director for the 
Maternal Fetal Tissue Bank, that level of 
energy is a must.  
Dr. Santillan’s career began in Chicago 
as an undergraduate at Loyola 
University Chicago, where he conducted 
research in chemistry and biochemistry. 
Just before entering medical school, he 
participated in translational science 
testing of a new anti-platelet drug on 
Rhesus monkeys. According to Dr. 
Santillan, “Seeing the direct clinical 
correlation with basic research was what 
got me really interested in research.”  
He was inspired as a medical student to 
pursue obstetrics, due in large part to 
the influence of Dr. John Gianopoulos, 
former Chair of Obstetrics and 
Gynecology at Loyola and Chief of 
Maternal Fetal Medicine, who had a true 
passion for teaching and taking care of 
patients. In the course of his training, Dr. 
Santillan became interested in high-risk 
pregnancies and realized that modern 
science has not explained the true 
mechanisms that drive many diseases 
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in pregnancy such as preeclampsia and 
obesity related risks in pregnancy. It is 
this very issue that drives Dr. Santillan’s 
clinical and research activities today.      
While all of his early training was at 
Loyola University Chicago, Dr. Santillan 
brought his talents to the University of 
Iowa when he became a fellow in 
Maternal-Fetal Medicine and later an 
Assistant Professor in the Department of 
Obstetrics and Gynecology. In research 
funded by the NIH Reproductive 
Scientist Development Program (K12), 
Dr. Santillan is investigating the 
immunovascular mechanisms of 
preeclampsia, obesity, and hypertension 
in pregnancy. His studies utilize a novel 
immunologically-derived mouse model 
of preeclampsia. These mice are 
essentially normal until pregnancy, at 
which time they develop hypertension, 
proteinuria, kidney dysfunction, and 
vascular dysfunction, all hallmarks of 
preeclampsia. These translational 
studies in mice are being partnered with 
studies in humans to determine whether 
the same immunological factors that 
drive the preeclamptic phenotype in 
mice are also present in humans during 
pregnancy and fuel the development of 
preeclampsia. Dr. Santillan’s research 
program has been heavily influenced by 
his early mentorship and ongoing 
collaborations at the University of Iowa 
with Drs. William Haynes, Stephen 
Hunter, Curt Sigmund, Justin Grobe, 
Eric Devor and Kimberly Leslie.  
Other areas of active research include 
the potential use of microRNAs as a 
predictive marker and causal agent in 
preeclampsia. This line of research, 
funded by a Preeclampsia Foundation 
Vision Grant, explores whether the 
simultaneous regulation of multiple 
pathways by microRNAs might play a 
mechanistic role in the development of 
preeclampsia. He is also exploring the 
relationship between diet and 
preeclampsia in collaboration with Dr. 
Linda Snetselaar, Chair of Preventive 
Nutrition Education, and Dr. Katie 
Tharp, Department of Epidemiology, 
College of Public Health at University of 
Iowa. Their ongoing research is based 
on epidemiologic data that poor 
obstetric outcomes, including 
preeclampsia, growth restriction, 
preterm labor, and still births, are lower 
in people that eat a diet rich in fruit, 
vegetables, and antioxidants. Moreover, 
the children of these women have 
reduced incidence of eczema, asthma, 
and cardiovascular events, all conditions 
that have immunologic underpinnings. 
The goal of Dr. Santillan’s study is to 
determine if eating a healthy diet can 
improve obstetrical outcomes in obese 
women and improve the cardiovascular 
health in their children.  
In addition to his active practice in the 
high-risk obstetrics clinic and 
collaborative research endeavors, Dr. 
Santillan is the Clinical Research 
Director for University of Iowa IRB-
approved Department of Obstetrics and 
Gynecology Maternal Fetal Tissue 
Bank. This bank is the obstetric arm of a 
family of biorepositories under the 
umbrella of the Women’s Health Tissue 
Repository (WHTR). The purpose of this 
bank is to help accelerate research by 
providing researchers with biosamples 
throughout pregnancy along with 
pertinent clinical information in an 
unidentified manner such that patient 
privacy is protected. To date, the 
Maternal Fetal Tissue Bank has 1300 
participants and over 20,000 aliquots of 
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material (i.e., maternal plasma, cord 
blood, placenta). Several projects and 
collaborations have sprung from the 
samples in this bank, most notably a 
collaborative effort with Dr. Jay 
Shendure at the University of 
Washington. Due to the purity of the 
DNA obtained from maternal plasma 
samples, it was possible to sequence 
the entire fetal genome. These data, 
recently published in Science 
Translational Medicine, illustrate the 
research that is possible using these 
precious tissue bank samples.  
In his spare time, Dr. Santillan is 
completing a PhD in Translational 
Biomedicine as part of the University of 
Iowa Institute for Clinical and 
Translational Science’s NIH-funded KL2 
training program. 
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